clinical trial data
See the following -
A Way For Biopharma To Disclose More Trial Data
[...] At a time when some regulatory bodies and biopharma companies are increasing their transparency initiatives involving access to clinical-trial data, disclosing trial results to volunteers could also go a long way toward strengthening public confidence. Read More »
- Login to post comments
Across Pharma, Few Open Arms For Trial Data Sharing
Industry inches toward consensus on limited sharing as EMA, GSK press for open access. Read More »
- Login to post comments
In Stunning Win For Open Science, Johnson & Johnson Decides To Release Its Clinical Trial Data To Researchers
Drug companies tend to be secretive, to say the least, about studies of their medicines. For years, negative trials would not even be published. Except for the U.S. Food and Drug Administration, nobody got to look at the raw information behind those studies. The medical data behind important drugs, devices, and other products was kept shrouded. Read More »
- Login to post comments
Using Scientific Publications Strategy to Ensure a Pharmaceutical Company's Credibility and a Product's Viability
Scientific publications remain the principal way that biopharmaceutical organizations relay critical clinical trial data to key external stakeholders such as physicians and payers. Data from different phases of drug development are the earliest ways these stakeholders learn about new products and the information serves as the building blocks for how a new product will be positioned in the marketplace...
- Login to post comments
Yale Program’s Agreement With Johnson & Johnson Allows Broad Access To Clinical Trial Data
In a move that promotes open science, the Yale University Open Data Access (YODA) Project has entered an agreement with Johnson & Johnson that will enable scientists around the world to gain access to the company’s clinical trial data assets. Read More »
- Login to post comments